-
FDA Approves OFEV for Chronic Fibrosing ILDs.
A popular topic of discussion on our forums is the two FDA-approved anti-fibrotic therapies for the management idiopathic pulmonary fibrosis (IPF): Esbriet and Ofev. Both of these drugs have been proven to slow lung function decline in IPF patients, with Ofev showing that decline at 57% according to phase III of the INBUILD trial.
Recently, the FDA approves the use of OFEV for other chronic fibrosing interstitial lung diseases (ILDs) in addition to IPF. For patients who otherwise had no treatment options, this is some hopeful news. Read the formal announcement from Boehringer Ingelheim HERE.
As a patient who is on OFEV and is convinced it is helping slow the progression of IPF, I am glad others with ILDs will get a chance to see if this medication also helps them. However, I am reluctant to share this excitement with other friends who may want to try it (I have a couple of friends with pulmonary sarcoidosis or NSIP) as I know the side effects of OFEV can be difficult to adjust to.
If you’re using OFEV to slow the progression of IPF, what is one tip you’d give patients wanting to start this drug for other ILD management?
Log in to reply.